Alzamend Neuro Regains Nasdaq Compliance
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
Stocks · News reference
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, SpainPresentation will report
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from
Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder
-SEC Filing
Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar